Benjamin Saylor | Authors


Durvalumab With or Without Tremelimumab Fails to Meet OS Endpoints in Urothelial Cancer

September 19, 2020

The co-primary end points of overall survival in patients with metastatic urothelial cancer were not met in the phase 3 DANUBE trial of durvalumab in combination with tremelimumab and durvalumab monotherapy, according to results presented at the 2020 ESMO Virtual Congress.

Durable Benefit Observed at 4 Years With Nivolumab Plus Ipilimumab in Advanced RCC

September 19, 2020

At 4 years of follow-up, nivolumab and ipilimumab in combination as first-line therapy of advanced renal cell carcinoma demonstrated durable benefit versus sunitinib, according to research presented at the 2020 ESMO Virtual Congress.